This top secret meeting was held to discuss a study done by Dr. Thomas Verstraeten and his co-workers using Vaccine Safety Datalink data as a project collaboration between the CDC's National Immunization Program (NIP) and four HMOs. The study examined the records of 110,000 children. Within the limits of the data, they did a very through study and found the following:
1. Exposure to thimerosal-containing vaccines at one month was associated significantly with the misery and unhappiness disorder that was dose related. That is, the higher the child's exposure to thimerosal the higher the incidence of the disorder. This disorder is characterized by a baby that cries uncontrollably and is fretful more so than that see in normal babies.
2. Found a nearly significant increased risk of ADD with 12.5ug exposure at one month.
3. With exposure at 3 months, they found an increasing risk of neurodevelopmental disorders with increasing exposure to thimerosal. This was statistically significant. This included speech disorders.
It is important to remember that the control group was not children without thimerosal exposure, but rather those at 12.5ug exposure. This means that there is a significant likelihood that even more neurodevelopmental problems would have been seen had they used a real control population. No one disagreed that these findings were significant and troubling. Yet when the final study was published in the journal Pediatrics Dr. Verstraeten and co-workers reported no consistent associations were found between thimerosal-containing vaccine exposure and neurodevelopmental problems. In addition, he list himself as an employee of the CDC, not disclosing the fact that at the time the article was accepted, he worked for GlaxoSmithKline, a vaccine manufacturing company.
So how did they do this bit of prestidigitation? They simply added another HMO to the data, the Harvard Pilgrimage. Congressman Dave Weldon noted in his letter to the CDC Director that this HMO had been in receivership by the state of Massachusetts because its records were in shambles. Yet, this study was able to make the embarrassing data from his previous study disappear. Attempts by Congressman Weldon to force the CDC to release the data to an independent researcher, Dr. Mark Geier, a researcher with impeccable credentials and widely published in peer-reviewed journals, have failed repeatedly.
It is obvious that a massive cover-up is in progress, as we have seen with so many other scandals-fluoride, food-based excitotoxins, pesticides, aluminum and now vaccines. I would caution those critical of the present vaccine policy not to put all their eggs in one basket, that is, with thimerosal as being the main culprit. There is no question that it plays a major role, but there are other factors that are also critical, including aluminum, fluoroaluminum complexes, and chronic immune activation of brain microglia.
In fact, excessive, chronic microglial activation can explain many of the effects of excessive vaccine exposure as I point out in two recently published articles. One property of both aluminum and mercury is microglial activation. With chronic microglial activation large concentrations of excitotoxins are released as well as neurotoxic cytokines. These have been shown to destroy synaptic connections, dendrites and cause abnormal pathway development in the developing brain as well as adult brain.
In essence, too many vaccines are being given to children during the brain's most rapid growth period. Known toxic metals are beings used in the vaccines that interfere with brain metabolism, antioxidant enzymes, damage DNA and DNA repair enzymes and trigger excitotoxicity. Removing the mercury will help but will not solve the problem because overactivation of the brain's immune system will cause varying degrees of neurological damage to the highly-vulnerable developing brain.
References For This Article
1. Lorscheider,FL; Vimy,MJ; Pendergrass,JC; Haley,BE. Mercury vapor exposure inhibits tubulin binding to GTP in rat brain: A molecular lesion also present in human Alzheimer brain From: FASEB J. 9(4): A-3845. FASEB Annual Meeting, Atlanta, Georgia, 10 March 1995.
2. Grandjean P, Budtz-Jorgensen E, White RF, Jorgensen PJ, Weihe P, Debes F, Keiding N Methylmercury exposure biomarkers as indicators of neurotoxicity in children aged 7 years. From: Am J Epidemiol 1999 Aug 1;150(3):301-5.
3. Albers JW, Kallenbach LR, Fine LJ, Langolf GD, Wolfe RA, Donofrio PD, Alessi AG, Stolp-Smith KA, Bromberg MB Neurological abnormalities associated with remote occupational elemental mercury exposure. Ann Neurol 1988 Nov;24(5):651-9.
4. Aschner M, Lorscheider FL, Cowan KS, Conklin DR, Vimy MJ, Lash LH Metallothionein induction in fetal rat brain and neonatal primary astrocyte cultures by in utero exposure to elemental mercury vapor (Hg0). From: Brain Res 1997 Dec 5;778(1):222-32.
5. Soederstroem S, Fredriksson A, Dencker L & Ebendal T The effect of mercury vapour on cholinergic neurons in the fetal brain: studies on the expression of nerve growth factor and its low- and high-affinity receptors. Developmental Brain Research 85(1):96-108 (1995).
6. Drasch G, Schupp I, Hofl H, Reinke R & Roider G. Mercury burden of human fetal and infant tissues. Eur J Pediatr 153:607-610 (1994).
7. Szucs A, Angiello C, Salanki J, Carpenter DO Effects of inorganic mercury and methylmercury on the ionic currents of cultured rat hippocampal neurons. Cell Mol Neurobiol 1997 Jun;17(3):273-88.
8. Low-Level Exposure to Methylmercury Modifies Muscarinic Cholinergic Receptor Binding Characteristics in Rat Brain and Lymphocytes: Physiologic Implications and New Opportunities in Biologic Monitoring Teresa Coccini,1 Giovanna Randine,2 Stefano M. Candura,1,3 Rossella E. Nappi,2,3 Leon D. Prockop,4 and Luigi Manzo.
9. Sorg O, Schilter B, Honegger P, Monnet-Tschudi F Increased vulnerability of neurones and glial cells to low concentrations of methylmercury in a prooxidant situation. Acta Neuropathol (Berl) 1998 Dec;96(6):621-7.
10. Liang YX, Sun RK, Sun Y, Chen ZQ, Li LH Psychological effects of low exposure to mercury vapor: application of a computer-administered neurobehavioral evaluation system. Environ Res 1993 Feb;60(2):320-7.
11. Sundberg J, Jonsson S, Karlsson MO, Oskarsson A Lactational exposure and neonatal kinetics of methylmercury and inorganic mercury in mice. Toxicol Appl Pharmacol 1999 Jan 15;154(2):160-9.
12. Inouye M., Murao K., Kajiwara Y., Behavorial and neuropathological effects of prenatal methyl Mercury exposure in mice.. Neurobehav.Toxicol Teratol. ,1985:7;227-232.
13. Koos et al., Mercury toxicity in pregnant women, fetus and newborn infant. Am J Obstet And Gynecol., 1976:126;390-409.
14. Khera et al., Teratogenic and genetic effects of Mercury toxicity. The biochemistry of Mercury in the environment. Nriagu, J.O.Ed Amsterdam Elsevier, 503-18,1979.
15. Drasch G, Schupp I, Hofl H, Reinke R, Roider G Mercury burden of human fetal and infant tissues. Eur J Pediatr 1994 Aug;153(8):607-10.
16. Yoshida M, Yamamura Y, Satoh H Distribution of mercury in guinea pig offspring after in utero exposure to mercury vapor during late gestation Arch Toxicol 1986 Apr;58(4):225-8.
17. Yuan,Y; Atchison,WD. Comparative effects of inorganic divalent mercury, methylmercury and phenylmercury on membrance excitability and synaptic transmission of CA1 neurons in hippocampal slices of the rat Neurotoxicology. 14(2):403-411, 1994.
18. Desi I, Nagymajtenyi L, Schulz H Effect of subchronic mercury exposure on electrocorticogram of rats. Neurotoxicology 1996 Fall-Winter;17(3-4):719-23.
19. Bucio L, Garcia C, Souza V, Hernandez E, Gonzalez C, Betancourt M, Gutierrez-Ruiz MC Uptake, cellular distribution and DNA damage produced by mercuric chloride. Mutat Res 1999 Jan 25;423(1-2):65-72.
20. Hua MS, Huang CC, Yang YJ Chronic elemental mercury intoxication: neuropsychological follow-up case study. Brain Inj 1996 May;10(5):377-84.
21. Grandjean P, Weihe P, White RF, Debes F Cognitive performance of children prenatally exposed to "safe" levels of methylmercury. Environ Res 1998 May;77(2):165-72.
22. Hock C, Drasch G, Golombowski S, Muller-Spahn F, Willershausen-Zonnchen B, Schwarz P, Hock U, Growdon JH, Nitsch RM Increased blood mercury levels in patients with Alzheimer's disease. J Neural Transm 1998;105(1):59-68.
23. Oskarsson A, Palminger Hallen I & Sundberg J. Exposure to toxic elements via breast milk. Analyst 120(3):765-770 (1995).
24. Hock C, Drasch G, Golombowski S, Muller-Spahn F, Willershausen-Zonnchen B, Schwarz P, Hock U, Growdon JH, Nitsch RM Increased blood mercury levels in patients with Alzheimer's disease. J Neural Transm 1998;105(1):59-68.
25. Wenstrup D, Ehmann WD, Markesbery WR Trace element imbalances in isolated subcellular fractions of Alzheimer's disease brains. Brain Res 1990 Nov 12;533(1):125-31
26. Basun H, Forssell LG, Wetterberg L, Winblad B Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1991;3(4):231-58.
27. Hock C, Drasch G, Golombowski S, Muller-Spahn F, Willershausen-Zonnchen B, Schwarz P, Hock U, Growdon JH, Nitsch RM Increased blood mercury levels in patients with Alzheimer's disease. J Neural Transm 1998;105(1):59-68.
28. Pendergrass JC, Haley BE, Vimy MJ, Winfield SA, Lorscheider FL Mercury vapor inhalation inhibits binding of GTP to tubulin in rat brain: similarity to a molecular lesion in Alzheimer diseased brain. Neurotoxicology 1997;18(2):315-24.
29. Opitz H, Schweinsberg F, Grossmann T, Wendt-Gallitelli MF, Meyermann R Demonstration of mercury in the human brain and other organs 17 years after metallic mercury exposure. Clin Neuropathol 1996 May-Jun;15(3):139-44.
30. Sanfeliu C, Sebastia J, Cristofol R, Rodriguez-Farre E. Neurotoxicity of organomercurial compounds. Neurotox Res. 2003;5(4):283-305.
31. el-Fawal HA, Gong Z, Little AR, Evans HL Exposure to methylmercury results in serum autoantibodies to neurotypic and gliotypic proteins.Neurotoxicology 1996 Summer;17(2):531-9.
32. Faustman EM, Ponce RA, Ou YC, Mendoza MA, Lewandowski T, Kavanagh T. Investigations of methylmercury-induced alterations in neurogenesis. Environ Health Perspect. 2002 Oct;110 Suppl 5:859-64.
33. Reading R. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Child Care Health Dev. 2004 Jan;30(1):90-1.
34. Qvarnstrom J, Lambertsson L, Havarinasab S, Hultman P, Frech W. Determination of methylmercury, ethylmercury, and inorganic mercury in mouse tissues, following administration of thimerosal, by species-specific isotope dilution GC-inductively coupled plasma-MS. Anal Chem. 2003 Aug 15;75(16):4120-4.
35. Shanker G, Syversen T, Aschner M. Astrocyte-mediated methylmercury neurotoxicity. Biol Trace Elem Res. 2003 Oct;95(1):1-10.
36. Zheng W, Aschner M, Ghersi-Egea JF. Brain barrier systems: a new frontier in metal neurotoxicological research. Toxicol Appl Pharmacol. 2003 Oct 1;192(1):1-11.
37. Kawase T, Ishikawa I, Orikasa M, Suzuki A. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Geier DA, Geier MR. J Biochem (Tokyo). 1989 Jul; 106(1): 8-10. Aluminum enhances the stimulatory effect of NaF on prostaglandin E2 synthesis in a clonal osteoblast-like cell line, MOB 3-4, in vitro. Pediatr Rehabil. 2003 Apr-Jun;6(2):97-102.
38. Geier MR, Geier DA. Thimerosal in childhood vaccines, neurodevelopmental disorders, and heart disease in the United States. J Amer Physc Surg 8: 6-11, 2003.
39. Allen JW, Shanker G, Tan KH, Aschner M. The consequences of methylmercury exposure on interactive functions between astrocytes and neurons. Neurotoxicology 23: 755-759, 2002.
40. Hansen JC, Reske-Nielsen E, et al. Distribution of dietary mercury in a dog. Quantitation and localization of total mercury in organs and central nervous system. Sci Total Environ 78: 23-43, 1989.
41. Zanoli P, Cannazza G, Baraldi M. Prenatal exposure to methyl mercury in rats: focus on changes in kyrenine pathway. Brain Res Bull 55: 235-238, 2001.
42. Olivieri G, Brack C, et al. Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHY5Y neuroblastoma cells. J Neurochem 74: 231-236, 2000.
43. Juarez BI, Mattinez M, et al. Methylmercury increases glutamate extracellular levels in frontal cortex of awake rats. Neurotoxicology and Teratology 24: 767-771, 2002.
44. Geier DA, Geier MR. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Pediatric Rehabil 6: 97-102, 2003.
45. Geier DA, Geier MR. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism. Med Sci Monit 10: P133-139, 2004.
46. Baskin DS, Ngo H, Didenko VV. Thimerosal indices DNA breaks, caspase-3 activation, membrane damage, and cell death in cultured human neurons and fibroblast. Toxicol Sci 74: 361-368, 2003.
47. Pichichero ME, et al. Mercury concentrations and metabolism in infants receiving vaccines containing thimerosal: a descriptive study. Lancet 360: 1737-1741, 2002.
48. Murata K, Dakeishi M. Impact of prenatal methylmercury exposure on child neurodevelopment in the Faroe Islands. Nippon Eiseigaku Zasshi 57: 564-570, 2002.
49. Davidson PW, Myers GJ, et al (Clarkson TW-member of panel) Effects of prenatal and postnatal exposure from fish consumption on neurodevelopment: outcomes at 66 months of age in the Seychelles Child Development Study. JAMA 280: 701-707, 1998.
50. Palumbo DR, Cox C, et al. (ClarksonTW) Association between prenatal exposure to methylmercury and cognitive functioning in Seychellois children: a reanalysis of the McCarthy Scales of Children's Ability from the main cohort study. Environ Res 84: 81-88, 2000.
51. Hornig M, Chian D, Lipkin WI. Neurotoxic effects of postnatal thimerosal are mouse strain dependent. Mol Psychiatry (In press).
52. Ueha-Ishibashi T, et al. Property of thimerosal-induced decrease in cellular content of gluatathione in rat thymocytes: a flow cytometric study with 5-chloromethylfluorescein. Toxicol in Vitro 18: 563-569, 2004.
53. Ueha-Ishibaschi T, et al. Effect of thimerosal, a preservative in vaccines, on intracellular Ca+2 concentration of ra cerebellar neurons. Toxicology 195: 77-84, 2004.
54. Havarinasab S, Lambertsson L, et al. Dose-response study of thimerosal-induced murine systemic autoimmunity. Toxicol Appl Pharmacol 194: 169-179, 2004.
55. Verstraeten T, Davis RL, DeStefano F, et al. Safety of thimerosal-containing vaccines: a two-phase study of computerized health maintenance organization databases. Pediatrics 112: 1039-1048, 2003. (This is the published study that was discussed in the conference. Here the damaging data is erased and the public is told the thimerosal-containing vaccines are perfectly safe. In this paper Dr. Verstraeten identified himself as working for the CDC, but in fact he is working for GlaxoSmithKline. The editors of the journal Pediatrics should have been willing to disclose this information once it was brought to their attention but they would not.).
Aluminum References
1. Murayama H, Shin RW, Higuchi J, Shibuya S, Muramoto T, Kitamoto T. Interaction of aluminum with PHFtau in Alzheimer's disease neurofibrillary degeneration evidenced by desferrioxamine-assisted chelating autoclave method.Am J Pathol. 1999 Sep;155(3):877-85.
2. Shin RW, Kruck TP, Murayama H, Kitamoto T. A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer's disease. Brain Res. 2003 Jan 24;961(1):139-46.
3. Li W, Ma KK, Sun W, Paudel HK. Phosphorylation sensitizes microtubule-associated protein tau to Al(3+)-induced aggregation. Neurochem Res. 1998 Dec;23(12):1467-76.
4. Singer SM, Chambers CB, Newfry GA, Norlund MA, Muma NA. Tau in aluminum-induced neurofibrillary tangles. Neurotoxicology. 1997;18(1):63-76.
5. Toda S, Yase Y. Effect of aluminum on iron-induced lipid peroxidation and protein oxidative modification of mouse brain homogenate. Biol Trace Elem Res. 1998 Feb;61(2):207-17.
6. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem. 2000 Jan;74(1):270-9.
7. Xie CX, Yokel RA. Aluminum facilitation of iron-mediated lipid peroxidation is dependent on substrate, pH and aluminum and iron concentrations. Arch Biochem Biophys. 1996 Mar 15;327(2):222-6.
8. Kawase T, Ishikawa I, Orikasa M, Suzuki A. Aluminum enhances the stimulatory effect of NaF on prostaglandin E2 synthesis in a clonal osteoblast-like cell line, MOB 3-4, in vitro. J Biochem (Tokyo). 1989 Jul; 106(1): 8-10.
9. Jope RS. Modulation of phosphoinositide hydrolysis by NaF and aluminum in rat cortical slices. J Neurochem. 1988 Dec; 51(6): 1731-6.
10. Blair HC, Finch JL, Avioli R, Crouch EC, Slatopolsky E, Teitelbaum SL. Micromolar aluminum levels reduce 3H-thymidine incorporation by cell line UMR 106-01. Kidney Int. 1989 May; 35(5): 1119-25.
11. Shainkin-Kestenbaum R, Adler AJ, Berlyne GM, Caruso C. Effect of aluminium on superoxide dismutase. Clin Sci (Lond). 1989 Nov; 77(5): 463-6.
12. Kawase T, Orikasa M, Suzuki A. Aluminofluoride- and epidermal growth factor-stimulated DNA synthesis in MOB 3-4-F2 cells. Pharmacol Toxicol. 1991 Nov; 69(5): 330-7.
13. Gomes MG, Moreira CA, Mill JG, Massaroni L, Oliveira EM, Stefanon I, Vassallo DV. Effects of aluminum on the mechanical and electrical activity of the Langendorff-perfused rat heart. Braz J Med Biol Res. 1994 Jan; 27(1): 95-100.
14. Jope RS. Modulation of phosphoinositide hydrolysis by NaF and aluminum in rat cortical slices. J Neurochem. 1988 Dec; 51(6): 1731-6.
15. Husaini Y, Rai LC, Mallick N. Impact of aluminium, fluoride and fluoroaluminate complex on ATPase activity of Nostoc linckia and Chlorella vulgaris. Biometals. 1996 Jul; 9(3): 277-83.
16. Blair HC, Finch JL, Avioli R, Crouch EC, Slatopolsky E, Teitelbaum SL. Micromolar aluminum levels reduce 3H-thymidine incorporation by cell line UMR 106-01. Kidney Int. 1989 May; 35(5): 1119-25.
17. Lai JC, Lim L, Davison AN. Effects of Cd2+, Mn2+, and Al3+ on rat brain synaptosomal uptake of noradrenaline and serotonin. J Inorg Biochem. 1982 Nov; 17(3): 215-25.
18. Shainkin-Kestenbaum R, Adler AJ, Berlyne GM, Caruso C. Effect of aluminium on superoxide dismutase. Clin Sci (Lond). 1989 Nov; 77(5): 463-6.
19. Department of Health and Human Services National Vaccine Program Office Presents: Workshop on Aluminum in Vaccines. Caribe Hilton International Hotel, San Juan, Puerto Rico: Jointly sponsored by: task Force for Child Survival and Development. May 12, 200.
20. Varner JA, Jenson KF, Harvath W, Isaacson RL. Chronic administration of aliminum-fluoride or sodium-fluoride to rats in drinking water: alterations in neuronal and cerebrovascular integrity. Brain Res 784: 284-298, 1998.
21. Strunecka A, Pataocka J. Aluminofluoride complexes: new phosphate analogues for laboratory investigations and potential danger for living organisms.
http://www.fluoridation.com/brain3.htm
22. Candura SM, Castildi AF, et al. Interaction of aluminum ions with phosphoinositide metabolism in rat cerebral cortical membranes. Life Sci 49: 1245-1252, 1991.
23. Publicover SJ. Brief exposure to the G-protein activator NaF/ AlCl3 induces prolonged enhancement of synaptic transmission in area of rat hippocampal slices. Expl Brain Res 84: 680-684, 1991.
24. Brenner A. Macrophagic myofascitiitis: a summery of Dr. Gherardi's presentations. Vaccine 20Supp 3): S5-6, 2002.
25. Lacson AG, D'Cruz CA, et al. Aluminum phagocytosis in quadriceps muscle following vaccination in children: relationship to macrophagic myofasciitis. Pediatr Dev Pathol 5: 151-158, 2002.
26. Flarend RE, Hem SL, et al. In vivo absorption of aluminum-containing vaccine adjuvants using 26 Al. Vaccine 15: 131401318, 1997.
27. Authier FJ Cherin P, et al. Central nervous system disease in patients with macrophagic myofasciitis. Brain 124: 974-983, 2001.
28. Gherardi RK. Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome. Rev Neurol (Paris) 159: 162-164, 2003.
29. Bergfors E, Trollfors B, Inerot A. Unexpectantly high incidence of persistent itching and delayed hypersensitivity to aluminum in children after the used of absorbed vaccines from a single manufacturer. Vaccine 22: 64-69, 2003.
30. Deloncle R, Fauconneau B, et al. Aluminum L-glutamate complexes in rat brain cortex: in vivo prevention of aluminum deposit by magnesium D-aspartate. Brain Res 946: 247-252, 2002.
31. Mundy WR, Freudenrich TM, Kodavanti PR. Aluminum potentates glutamate-induced calcium accumulation and iron-induced oxygen free radical formation in primary neuronal cultures. Mol Chem Neuropathol 32: 41-57, 1997.
References Concerning Lead
1. Naatala JT, Loikkanen JJ, et al. Lead amplifies glutamate-induced oxidative stress. Free Radical Biology Medicine 19: 689-693, 1995.
2. Morgan RE, Garavan H, et al. Early lead exposure produces lasting changes in sustained attention, response initiation, and reactivity to errors. Neurotoxicology and Teratology 23: 519-531, 2001.
3. Needleman HL, McFarland C, et al. Bone lead levels in adjudicated delinquents: A case control study. Neurotoxicology and Teratology 24: 711-717, 2002.
4. Dietrich KN, Ris MD, et al. Early exposure to lead and juvenile delinquency. Neurotoxicology and Teratology 23: 511-518, 2001.
My References
1. Blaylock R. Interaction of cytokines, excitotoxins, and reactive nitrogen and oxygen species in autism spectrum disorders. J. Amer Nutr Assoc 6: 21-35, 2003.
2. Blaylock RL. The central role of excitotoxicity in autism spectrum disorders. J Amer Nutra Assoc 6: 7-19, 2003.
3. Blaylock RL. Chronic microglial activation and excitotoxicity secondary to excessive immune stimulation: possible factors in Gulf War Syndrome and autism. J Amer Phys Surg 9: 46-51, 2004.
Part 1
